Form 4: Pyxis Oncology CEO Receives Stock Grant
Insider Transaction (Form 4)
Thomas Civik, CEO & Chairman of the Board and a Director of Pyxis Oncology, Inc., received 2,503,050 shares of common stock on September 4, 2026.
Summary
- Grant/award: acquired 2,503,050 Stock Option (Right to Buy) on September 4, 2026; holds 2,503,050 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Thomas Civik — Director, Officer (CEO & Chairman of the Board)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-04 | Grant/award | Stock Option (Right to Buy) | 2,503,050 | — | — | 2,503,050 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-04 | Grant/award (2,503,050 shares) |
Keywords
insider transaction, Form 4, PYXS, Pyxis Oncology, Inc., neutral, Thomas Civik
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.